French company Innate Pharma has completed patient enrolment in the dose escalation segment of the Phase I IPH4502-101 study, involving its Nectin-4 exatecan antibody-drug conjugate (ADC), IPH4502.
Celldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or ...
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint.14 patients with available ...
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...
Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first ...
FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...
NeuroTraX-AI targets the blood-brain barrier, a central hurdle in brain medicine and drug safety, as U.S. regulators ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomo ...
The Healthy @Reader's Digest on MSN
FDA Updates Nationwide Blood Pressure Drug Recall
A rare expiration date error has caused nearly 8,000 hypertension prescriptions to be pulled from market.
The Carr family took in Steven Judy, hoping to ‘save’ a troubled teen. They didn’t know he would become one of the most hated men in America ...
This is the story of the 18 days between the killing of Renee Good and Alex Pretti, the highly questionable ways the Trump ...
The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results